跳至主要内容
临床试验/NCT02194608
NCT02194608已完成不适用

A Randomized Clinical Trial on Home Telemonitoring for the Management of Metabolic and Cardiovascular Risk in Individuals With Type 2 Diabetes

Merck Sharp & Dohme LLC0 个研究点目标入组 500 人开始时间: 2011年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
500
主要终点
Change from baseline in blood glucose level

研究概览

简要总结

The primary goal is to evaluate whether a home telehealth system that enables the participant to monitor their body weight, blood glucose values and blood pressure values, associated with remote educational support and feedback to the general practitioner, can improve metabolic control and overall cardiovascular risk in individuals with type 2 diabetes mellitus (T2DM), as compared to usual practice.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
None

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • has type 2 diabetes
  • treated with oral agents in monotherapy or combined therapy ± basal insulin
  • previously educated to self-monitoring blood glucose (SMBG) use

排除标准

  • has type 2 diabetes non-pharmacologically treated
  • has type 2 diabetes treated with multiple daily injections of insulin
  • is unable to use the telemedicine system
  • pregnancy
  • has major cardiovascular, cerebrovascular, or peripheral vascular event in the last 6 months
  • has any disease or condition, including alcohol or drugs abuse, that may interfere with study completion

结局指标

主要结局

Change from baseline in blood glucose level

时间窗: Baseline and 12 months

Change from baseline in blood pressure

时间窗: Baseline and 12 months

Change from baseline in body mass index

时间窗: Baseline and 12 months

次要结局

  • Number of emergency room visits and hospital admissions(Up to 12 months)
  • Percentage of participants who achieved hemoglobin A1c (HbA1c) <7.0%(Up to 12 months)
  • Percentage of participants who achieved blood pressure <130/80 mmHg(Up to 12 months)
  • Percentage of participants who achieved low-density lipoprotein (LDL) cholesterol <100 mg/dL(Up to 12 months)
  • Percentage of participants requiring therapy modifications(Up to 12 months)
  • Change from baseline in total cholesterol(Baseline, 6 months, and 12 months)
  • Change from baseline in high-density lipoprotein (HDL) cholesterol(Baseline, 6 months, and 12 months)
  • Number of office visits and home visits(Up to 12 months)
  • Change from baseline in the number and doses of drugs for treatment of diabetes(Baseline and 12 months)
  • Change from baseline in the number and doses of drugs for treatment of hypertension(Baseline and 12 months)
  • Change from baseline in LDL cholesterol(Baseline, 6 months, and 12 months)
  • Change from baseline in triglycerides(Baseline, 6 months, and 12 months)
  • Change from baseline in cardiovascular risk score(Baseline, 6 months, and 12 months)
  • Change from baseline in the number and doses of drugs for treatment of dyslipidemia(Baseline and 12 months)
  • Participant overall satisfaction level(Up to 12 months)
  • Participant compliance with protocol-provided devices(Up to 12 months)
  • Number of participants who experienced hypoglycemia(Up to 12 months)
  • Number of hypoglycemic episodes(Up to 12 months)
  • Number of participants who experienced severe/symptomatic hypoglycemia(Up to 12 months)
  • Number of severe/symptomatic hypoglycemic episodes(Up to 12 months)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验